Yes Mozz, OA has 10 times the number of suffers
world wide as has RA. However the remuneration
per patient treated with Zilosul, is a small fraction
compared with the cost of Humira.
That is another thing that used to annoy me
about Rennie. He would trumpet the size of
the OA market compared with RA, but then
not explain how much less the take for Zilosul
per patient would be. The master of deceit.
Actually, I would like to see the $2500 fee for Zilosul
selected, to encourage early adoption of the
drug (DMOAD or not). Apparently the margins
would still be lucrative, even if we only receive
20% of the gross return.
Where we at?, page-211
-
- There are more pages in this discussion • 496 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.005(2.17%) |
Mkt cap ! $82.20M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 23.5¢ | 23.0¢ | $85.35K | 365.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 280011 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 44703 | 3 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |